Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.51 |
| ▸ | HPGD | P15428 | 2/20 | 0.51 |
| ▸ | HTT | P42858 | 1/20 | 0.51 |
| ▸ | TP53 | P04637 | 3/20 | 0.37 |
| ▸ | DRD2 | P14416 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 2/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.34 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.34 |
| ▸ | CYP2C19 | P33261 | 3/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.33 |
| ▸ | MAPT | P10636 | 2/20 | 0.33 |
| ▸ | HTR1A | P08908 | 1/20 | 0.33 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.33 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.33 |
| ▸ | GLA | P06280 | 1/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14274958 | 0.93 | HPGD (0.52) | SMN1; SMN2HPGDHTTTP53DRD2 | |
| SCHEMBL14264553 | 0.93 | SMN1; SMN2 (0.53) | SMN1; SMN2HPGDHTTTP53DRD2 | |
| SCHEMBL24686923 | 0.91 | SMN1; SMN2 (0.62) | SMN1; SMN2HPGDHTTTP53DRD2 | |
| SCHEMBL23181275 | 0.89 | SMN1; SMN2 (0.49) | SMN1; SMN2HPGDHTTTP53DRD2 | |
| SCHEMBL13225533 | 0.88 | SMN1; SMN2 (0.49) | SMN1; SMN2HPGDHTTTP53DRD2 | |
| SCHEMBL2607942 | 0.87 | SMN1; SMN2 (0.48) | SMN1; SMN2HPGDHTTTP53DRD2 | |
| SCHEMBL24686260 | 0.87 | SMN1; SMN2 (0.50) | SMN1; SMN2HPGDHTTTSHRALDH1A1 | |
| SCHEMBL18470794 | 0.86 | HPGD (0.47) | SMN1; SMN2HPGDHTTTP53DRD2 | |
| SCHEMBL12918819 | 0.86 | SMN1; SMN2 (0.56) | SMN1; SMN2HPGDHTTDRD2TSHR | |
| SCHEMBL14870351 | 0.85 | HTT (0.46) | SMN1; SMN2HPGDHTTTP53DRD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9861705-B2 | Conjugates of an IL-2 moiety and a polymer | NEKTAR THERAPEUTICS (US) | 2018-01-09 | — | — | US | disclosed |
| US-20170035898-A1 | CONJUGATES OF AN IL-15 MOIETY AND A POLYMER | NEKTAR THERAPEUTICS | 2017-02-09 | — | — | US | disclosed |
| US-20140328791-A1 | Conjugates of an IL-2 Moiety and a Polymer | NEKTAR THERAPEUTICS | 2014-11-06 | — | — | US | disclosed |
| US-20120100096-A1 | CONJUGATES PF SMALL-INTERFERING NUCLEIC ACIDS | NEKTAR THERAPEUTICS (US) | 2012-04-26 | — | — | US | disclosed |
| US-20110269713-A1 | BRYOSTATIN ANALOGUES AND METHODS OF MAKING AND USING THEREOF | UNIVERSITY OF UTAH RESEARCH FOUNDATION (US) | 2011-11-03 | — | — | US | disclosed |
| US-20110171163-A1 | POLYMER CONJUGATES OF ZICONOTIDE PEPTIDES | NEKTAR THERAPEUTICS (US) | 2011-07-14 | — | — | US | disclosed |
| US-20110171161-A1 | POLYMER CONJUGATES OF PROTEGRIN PEPTIDES | NEKTAR THERAPEUTICS (US) | 2011-07-14 | — | — | US | disclosed |
| US-20110165113-A1 | POLYMER CONJUGATES OF V681-LIKE PEPTIDES | NEKTAR THERAPEUTICS (US) | 2011-07-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140328791-A1 | Conjugates of an IL-2 Moiety and a Polymer | IL2, IL2RA, ILF2 | SMN1; SMN2 3123/4885HPGD 712/4885HTT 3288/4885 |
| US-20110171163-A1 | POLYMER CONJUGATES OF ZICONOTIDE PEPTIDES | NGLY1, VIP, IAPP | SMN1; SMN2 1670/4885HPGD 1423/4885HTT 1909/4885 |
| US-20110171161-A1 | POLYMER CONJUGATES OF PROTEGRIN PEPTIDES | PSMG3, PSMB11, PSMC5 | SMN1; SMN2 1077/4885HPGD 1965/4885HTT 124/4885 |
| US-20110269713-A1 | BRYOSTATIN ANALOGUES AND METHODS OF MAKING AND USING THEREOF | PRKAR2B, PRKAR2A, PRKCH | SMN1; SMN2 3279/4885HPGD 2235/4885HTT 2587/4885 |
| US-20110165113-A1 | POLYMER CONJUGATES OF V681-LIKE PEPTIDES | NGLY1, VIP, DNPEP | SMN1; SMN2 2851/4885HPGD 4475/4885HTT 1055/4885 |
| US-20120100096-A1 | CONJUGATES PF SMALL-INTERFERING NUCLEIC ACIDS | SLC19A1, FOLR1, SLC46A1 | SMN1; SMN2 164/4885HPGD 3787/4885HTT 909/4885 |
| US-20170035898-A1 | CONJUGATES OF AN IL-15 MOIETY AND A POLYMER | IL15, IL15RA, IL2 | SMN1; SMN2 4077/4885HPGD 154/4885HTT 1539/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.